Clinical TrialApr 22, 2026, 08:17 AM
SAB Biotherapeutics Releases Phase 1 Clinical Trial Data for SAB-142
AI Summary
SAB Biotherapeutics, Inc. announced the release of a presentation and a corresponding press release on April 22, 2026. These materials provide additional information regarding the company's Phase 1 clinical trial for SAB-142. The trial involves a human anti-thymocyte biologic, and the presentation is accessible via the company's investor relations website.
Key Highlights
- SAB Biotherapeutics released a presentation on April 22, 2026.
- The presentation includes data from the Phase 1 clinical trial of SAB-142.
- SAB-142 is a human anti-thymocyte biologic.
- A press release also announced the data's availability.
- The presentation is available on the company's investor relations website.
Price Impact
More from SABS